Login
$PROF
$7.20 -$0.14 (1.91%) After hours

$PROF SEC Filings

Filed On Filing
12 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 5, 2026, Cynthia Lavoie notified the Board of Directors (the “Board”) of Profound Medical Corp. (the “Company”) of her resignation from the Board, effective immediately. This resignation was not the result of any disagreement...

09 Nov 2026 8-K: Regulation FD Disclosure

TORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, ...

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

03 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K ITEM 601(B)(10)(IV). SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

22 Oct 2026 8-K: Regulation FD Disclosure

Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisions

14 Oct 2026 8-K: Regulation FD Disclosure

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

09 Oct 2026 8-K: Regulation FD Disclosure

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO®

07 Oct 2026 8-K: Results of Operations and Financial Condition

Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%

04 Sep 2026 8-K: Regulation FD Disclosure

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures,...

03 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures,...

17 Aug 2026 8-K: Regulation FD Disclosure

Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day

17 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, ...

13 Aug 2026 8-K: Regulation FD Disclosure

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures...

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

– Operating expenses decline 16%, helping drive a 39% improvement in net loss –

24 Jul 2026 8-K: Regulation FD Disclosure

– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month –

16 Jul 2026 8-K: Regulation FD Disclosure

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, ...

15 Jul 2026 8-K: Regulation FD Disclosure

TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be h...

19 May 2026 EFFECT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support